Navigation Links
Pharmasset Reports Fiscal Year End 2009 Financial Results
Date:11/25/2009

sks and uncertainties, including, without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


                             PHARMASSET, INC.
            STATEMENTS OF OPERATIONS AND COMPREHENSIVE NET LOSS
            (in thousands, expect share and per share amounts)



                                              Years Ended September 30,
                                              -------------------------
                                            2009        2008        2007
                                            ----        ----        ----

Revenues                                 $13,293      $1,857     $22,009
                                        --------    --------     -------

COSTS AND EXPENSES:
  Research and development                52,552      42,996      20,319
  General and administrative              13,365      13,289       9,211
                                        --------    --------     -------

           Total costs and expenses       65,917      56,285      29,53
'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
2. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
3. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
4. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
5. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
6. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
7. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
8. Pharmasset Reports Fiscal Year End 2008 Financial Results
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014  Pfenex Inc. (NYSE MKT: ... anthrax vaccine, has been filed and is now open ... by the Department of Health and Human Services (HHS), ... "We are extremely pleased to have the ... This represents a significant milestone in our company,s partnership ...
(Date:12/19/2014)...  In the Friday, December 19 edition of ... Information Technology (HIT) features Konica Minolta, the company announced today. The ... several leading healthcare organizations. In addition to the ... such as New York , Chicago ... , Minneapolis and San Francisco ...
(Date:12/19/2014)... -- You,re visiting the dentist for what you think ... she says you need a root canal. Though it,s ... several questions and feel apprehensive about your upcoming procedure. ... to worry about. The Pennsylvania Dental Association (PDA) wants ... the public may have surrounding this common procedure that ...
Breaking Medicine Technology:Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2Root Canals Have Become More Routine 2
... , SEATTLE, Aug. 3 Cell ... a study released by Dartmouth-Hitchcock Medical Center at the International ... Conference on Lung Cancer. The study demonstrated that in patients ... OPAXIO (paclitaxel poliglumex) and Alimta(R) (pemetrexed) was well tolerated and ...
... , , , ... Joanne Scott went through a cancer treatment that changed her life -- ... person in the world to receive an injection of tumor-activated natural killer ... Her doctors at the Royal Free Hospital in London recommended this experimental ...
Cached Medicine Technology:OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer 2OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer 3British Woman Celebrates a Year of Living Cancer-Free 2British Woman Celebrates a Year of Living Cancer-Free 3British Woman Celebrates a Year of Living Cancer-Free 4
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 Fad ... have changed. The reason why most fad diets have ... temporarily. The problem with fad diets is that, as the ... leaving the dieter uncertain of how to reset the metabolism ... this reason, Diet Doc developed their all-inclusive diet plans ...
(Date:12/22/2014)... 22, 2014 Sagacious Consultants, the premier ... subscription option to their ad hoc report writing service ... Customers can sign up for an annual subscription and ... month at a deeply discounted hourly rate. , ... has a progressively discounted rate. Subscription hours are contracted ...
(Date:12/22/2014)... Charleston, SC (PRWEB) December 22, 2014 ... Deierlein was joined by Pastor Gordon Cashwell for an ... episode, Deierlein asks Gordon, “Why is it so important ... birthday of Jesus?” Cashwell replies, “We all should respect ... this country was founded on Christian beliefs. That means ...
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... new vaccine created to fight an illness similar to ... and even humans from similar brain infections, researchers report. ... becoming infected by the incurable brain disorder known as ... Dec. 21 online edition of the journal Vaccine ... particles known as prions that go rogue. Prion ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2
... be as effective as a second medication for as ... not been cured by a single antidepressant medication. ... recently published in the Journal of Clinical Psychiatry, found ... can work as well as administering a second antidepressant ...
... , TUESDAY, Aug. 23 (HealthDay News) -- Accidental ... cancer nurses in the United States, a new study ... state who work in outpatient chemotherapy infusion centers and ... eyes had been exposed to the drugs. In ...
... -- Researchers say boys are becoming physically mature earlier ... reaching sexual maturity about 2.5 months earlier every decade ... reason for earlier maturity for boys, as with girls, ... more favorable for it," demographer Joshua Goldstein, director of ...
... By Maureen Salamon HealthDay Reporter , TUESDAY, ... research investigating injectable drugs to treat psoriasis -- an ... the medications are not linked to higher heart risks. ... complete information from drug makers impeded their ability to ...
... than 1 million patients in North America, results from ... as bacteria, in people genetically predisposed to the disorder. ... colon, is one such condition. The aberrant immune ... small signaling proteins secreted by various cells, including ...
... TUESDAY, Aug. 23 (HealthDay News) -- A test that detects ... likely to raise the risk of invasive cervical cancer, when ... many women than the Pap test alone, a new study ... the HPV test alone appears to be enough, said study ...
Cached Medicine News:Health News:Exercise can substitute effectively as second 'medication' for people with depression 2Health News:Nurses at Risk for Accidental Exposure to Chemo Drugs: Study 2Health News:Boys Mature Sexually Earlier Than Ever Before: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 3Health News:Novel cytokine protects mice from colitis 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 3
... The AFX Lens is ... for use in an air-filled ... use as a primary air-fluid ... profile and sutureless design make ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
Medicine Products: